Drug intelligence / Profile preview

irolumab

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Irolumab is a monoclonal antibody identified as a PCSK9 inhibitor. It is currently being investigated in a clinical trial for its effect on serum lipids and cardiovascular events in patients with Acute Coronary Syndrome (ACS) before and after percutaneous coronary intervention (PCI). As a PCSK9 monoclonal antibody, its mechanism of action involves inhibiting the Proprotein Convertase Subtilisin/Kexin type 9 protein, which typically degrades LDL receptors. By blocking PCSK9, irolumab is expected to increase the number of LDL receptors on liver cells, thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream.

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on irolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on irolumab.

Explore the full profile